Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)

Phase 3

Terminated

Conditions: Myelodysplastic Syndromes

Interventions: Drug: Magrolimab
Drug: Placebo
Drug: Azacitidine

Registration Number: NCT04313881

Lead Sponsor: Gilead Sciences

Brief Summary: The primary objective of this study is to evaluate the efficacy of magrolimab in combination with azacitidine compared to that of azacitidine plus placebo in previously untreated participants with intermediate/high/very high risk myelodysplastic syndrome (MDS) by Revised International Prognostic Scoring System (IPSS-R) as measured by complete remission (CR) and overall survival (OS).

Detailed Description: Not available

Recruitment & Eligibility

Status: TERMINATED

Sex: All

Target Recruitment: 539

Inclusion Criteria

Participants with Myelodysplastic Syndrome (MDS) defined according to World Health Organization classification, with Revised International Prognostic Scoring System (IPSS-R) prognostic risk category of intermediate, high, or very high risk.
Adequate performance status and hematological, liver, and kidney function.

Key

Exclusion Criteria

Immediate eligibility for allogenic stem cell transplant (SCT), as determined by the investigator, with an available donor.
Prior treatment with Cluster of Differentiation (CD) 47 or Signal-regulatory protein alpha (SIRPα)-targeting agents.
Any prior antileukemic therapy for treatment of intermediate, high, very high risk MDS per IPSS-R.
Second malignancy, except treated basal cell or localized squamous skin carcinomas, localized prostate cancer, or other malignancies for which participants are not on active anticancer therapies and have had no evidence of active malignancy for at least ≥ 1 year.
Contraindications to azacitidine.
Clinical suspicion of active central nervous system (CNS) involvement by MDS.
Known active or chronic hepatitis B or C infection or human immunodeficiency virus in medical history .
Active hepatitis B virus and/or active hepatitis C virus, and/or HIV following testing at screening.
Pregnancy or active breastfeeding.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Control Arm (Placebo + Azacitidine)	Placebo	Participants will receive the following placebo dosing regimens to mirror magrolimab dosing regimen in addition to azacitidine: Placebo: On Days 1 and 4; Day 8; Days 11, 15, followed by weekly administration for 5 doses (on Days 22, 29, 36, 43, and 50). Additionally, placebo was administered on Day 57 and every 2 weeks thereafter. Azacitidine: 75 mg/m\^2 on Days 1 to 7 (or Days 1 to 5 and 8 to 9) of each cycle.
Magrolimab + Azacitidine	Azacitidine	Participants will receive the following magrolimab and azacitidine dosing regimens: Magrolimab: Magrolimab Priming Dose: * 1 mg/kg on Days 1 and 4 * 15 mg/kg on Day 8 * 30 mg/kg on Days 11, 15, followed by weekly administration for 5 doses (on Days 22, 29, 36, 43, and 50) Magrolimab Maintenance Dose: * 30 mg/kg on Day 57 and 30 mg/kg every 2 weeks thereafter. Azacitidine: 75 mg/m\^2 on Days 1 to 7 (or Days 1 to 5 and 8 to 9) of each 28-day cycle.
Control Arm (Placebo + Azacitidine)	Azacitidine	Participants will receive the following placebo dosing regimens to mirror magrolimab dosing regimen in addition to azacitidine: Placebo: On Days 1 and 4; Day 8; Days 11, 15, followed by weekly administration for 5 doses (on Days 22, 29, 36, 43, and 50). Additionally, placebo was administered on Day 57 and every 2 weeks thereafter. Azacitidine: 75 mg/m\^2 on Days 1 to 7 (or Days 1 to 5 and 8 to 9) of each cycle.
Magrolimab + Azacitidine	Magrolimab	Participants will receive the following magrolimab and azacitidine dosing regimens: Magrolimab: Magrolimab Priming Dose: * 1 mg/kg on Days 1 and 4 * 15 mg/kg on Day 8 * 30 mg/kg on Days 11, 15, followed by weekly administration for 5 doses (on Days 22, 29, 36, 43, and 50) Magrolimab Maintenance Dose: * 30 mg/kg on Day 57 and 30 mg/kg every 2 weeks thereafter. Azacitidine: 75 mg/m\^2 on Days 1 to 7 (or Days 1 to 5 and 8 to 9) of each 28-day cycle.

Primary Outcome Measures

Name	Time	Method
Percentage of Participants With Complete Remission (CR)	From randomization up to 31.01 months	The percentage of participants (CR rate) are participants who reach morphologic CR (morphological blast of ≤ 5% and recovery of absolute neutrophil count (ANC), platelets, and hemoglobin from complete blood counts as well as peripheral blast) based on Investigator-assessed International Working Group (IWG) myelodysplastic syndrome (MDS) criteria on or prior to initiation of any new anticancer therapy, including stem cell therapy (SCT). Percentages were rounded off.
Overall Survival (OS)	From randomization up to 32.62 months	OS is defined as the number of months measured from the date of randomization to the date of death from any cause. Kaplan Meier (KM) estimates were used for analysis.

Secondary Outcome Measures

Name	Time	Method
Duration of CR (DOCR)	From randomization up to 31.01 months	DOCR=Time from first CR date to the first date of relapse, disease progression (PD) or death, prior to initiation of any new anticancer therapy excluding SCT whichever occurs earlier. PD is defined as: \<5% blasts: ≥50 increase in blasts to \>5% blasts,5%-10% blasts: ≥50% increase in blasts to \>10% blasts, 10%-20% blasts: ≥50% increase in blasts to \>20% blasts,20%-30% blasts: ≥50% increase in blasts to \>30% blasts, any of the following: at least 50% decrement from maximum remission/response in granulocytes or platelets. Reduction in Hgb by ≥2 g/dL / Transfusion dependence. Relapse is defined as return to pretreatment bone marrow blast percentage / decrement of ≥ 50% from maximum remission/response levels in granulocytes or platelets/ reduction in Hgb concentration by ≥ 1.5 g/dL or transfusion dependence. CR is defined in outcome measure 1. KM estimates were used for analysis.
Duration of Response (DOR)	From randomization up to 31.01 months	DOR is measured from time measurement criteria are first met for objective response to first date of relapse, disease progression (PD) /death, prior to initiation of any new anticancer therapy excluding SCT whichever occurs earlier. Disease progression and relapse have been defined in outcome measure number 3. KM estimates were used for analysis.
Percentage of Participants With CR in Participants With TP53 Mutation	From randomization up to 31.01 months	CR in TP53 mutant population is defined as the percentage of participants who achieve a morphologic CR based on investigator assessments using IWG criteria on or prior to initiation of any new anticancer therapy, including SCT in TP53 mutant population. Percentages were rounded off.
Minimal Residual Disease (MRD)-Negative Response Rate	From randomization up to 31.01 months	The MRD-negative response rate is defined as the percentage of participants who achieved a morphologic CR or marrow CR based on Investigator-assessed IWG criteria and reached MRD-negative disease status prior to initiation of any new anticancer therapy, including SCT. MRD-negative disease status was assessed using a multiparameter flow cytometry-based assay performed by a central laboratory. Morphologic CR and marrow CR are defined in outcome measures 1 and 4, respectively. Percentages were rounded off.
Time to Transformation to AML	From randomization up to 31.01 months	Time to transformation to AML is defined as the time from randomization to the collection date of bone marrow sample leading to documented AML diagnosis. Transformation assessments post SCT were included in the analysis.KM estimates were used for analysis.
Functional Assessment of Cancer Therapy-Anemia (FACT-Anemia) Response Rate	Up to week 136	The FACT-Anemia response rate is defined as the percentage of participants who showed clinically meaningful improvement in health-related quality of life (HRQoL) based on the score from the FACT-Anemia instrument prior to initiation of any new anticancer therapy, including SCT. The minimal clinically meaningful difference of 7.0 was used as cutoff for clinically meaningful improvement. The FACT-Anemia instrument consists of 5 subscales, including physical well-being, emotional well-being, functional well-being, social well-being, and anemia symptoms. Each subscale measures items on a 5-point Likert scale from 0 to 4, where 0 = not at all and 4 = very much. The subscales are scored by summing points from all questions, then converting this sum to a 100 point scale; 0 indicates the poorest quality of life (QOL) and 100 denotes the highest QOL. Percentages were rounded off.
Objective Response Rate (ORR)	From randomization up to 31.01 months	ORR is defined as the percentage of participants who reach objective response including CR, partial remission (PR), marrow CR or hematological improvement prior to initiation of any new anticancer therapy including SCT for MDS per IWG 2006 criteria per investigator's evaluation. CR is defined in outcome measure 1. PR is defined as all CR criteria if abnormal before treatment except, one marrow blasts decreased by ≥ 50% over pretreatment but still \> 5% cellularity and morphology not relevant. Marrow CR is defined as bone marrow ≤ 5% myeloblasts and decrease by ≥ 50% over pretreatment, stable disease with any hematological improvement, peripheral blood: if hematological improvement responses, they were noted in addition to marrow CR. Stable Disease: Failure to achieve at least PR, but no evidence of progression for \> 8 weeks. Percentages were rounded off.
Red Blood Cell (RBC) Transfusion Independence Rate	From randomization up to 31.01 months	RBC transfusion independence rate is defined as the percentage of participants who have a 56-day or longer period with no RBC transfusions at any time between randomization and initiation of any new anticancer therapy, including SCT, among all participants who were RBC transfusion-dependent at Baseline. Percentages were rounded off.
Event Free Survival (EFS)	From randomization up to 31.01 months	EFS is defined as the time from randomization to transformation to acute myeloid leukemia (AML) or death from any cause, whichever occurs first. Transformation assessments and deaths post SCT were included in the analysis. KM estimates were used for analysis
Progression Free Survival (PFS)	From randomization up to 31.01 months	PFS is defined as the time from randomization to the date of documented DP (including treatment failure by IWG criteria or relapse after PR/CR), or death from any cause, whichever occurs first. Response assessments and deaths post SCT were included in the analysis. Treatment failure is defined as, Death during treatment or disease progression characterized by worsening cytopenia, increase in percentage of bone marrow blasts, or progression to a more advanced MDS FAB subtype than pretreatment. Relapse after CR or PR = Return to pretreatment bone marrow blast percentage / Decrement of ≥ 50% from maximum remission/response levels in granulocytes or platelets / Reduction in Hgb concentration by ≥ 1.5 g/dL or transfusion dependence. CR, PR and PD are defined in outcome measures 1, 4 and 5 respectively. KM estimates were used for analysis.
Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAE)	First dose date up to 135.9 weeks plus 70 days (Up to 2.8 years)	TEAE's are defined as any AEs with an onset date on or after the study drug start date, no later than 70 days after study drug last dose date or day before initiation of new anticancer therapy including SCT. If AE onset date is on or before last dose date, it is considered as TEAE regardless of start of new anticancer therapy. An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with use of an investigational product or other protocol imposed intervention, regardless of attribution. An event is considered "serious", if it results death, life-threatening, inpatient or prolongation hospitalization, incapacity or substantial disruption of the ability to conduct normal functions, a congenital anomaly/birth defect, and important medical events.
Serum Concentration of Magrolimab	Preinfusion on Days 0, 7, 28, 56, 112, 168, 252 and 336	Pretreatment assessments for the initial dose may be collected up to 72 hours before administration of study treatment; thereafter, pretreatment assessments are to be collected within 24 hours prior to study treatment administration.
Percentage of Participants With Positive Anti-magrolimab Antibodies	Up to 72 hours before administration of any treatment at Day 1, Cycle 1; within 24 hours prior to any study drug administration at Day 1 of Cycles 2, 3, 5, 7, 10, and 13 and End of Treatment (± 7 Days after last study drug dose); Cycle length is 28 Days	Percentages were rounded off.

Trial Locations

Locations (169): Thomas Jefferson University, Sidney Kimmel Cancer Center; Clinical Research Organization
🇺🇸
Philadelphia, Pennsylvania, United States
Swedish Cancer Institute
🇺🇸
Seattle, Washington, United States
Winship Cancer Institute
🇺🇸
Atlanta, Georgia, United States
The University of Chicago Medical Center
🇺🇸
Chicago, Illinois, United States
University of Maryland, Greenebaum Comprehensive Cancer Center
🇺🇸
Baltimore, Maryland, United States
Dana Farber Cancer Institute (DFCI)
🇺🇸
Boston, Massachusetts, United States
The Ohio State University Wexner Medical Center / James Cancer Hospital
🇺🇸
Columbus, Ohio, United States
UCLA Ronald Reagan Medical Center
🇺🇸
Los Angeles, California, United States
UC Irvine Health
🇺🇸
Orange, California, United States
University Health Network
🇨🇦
Toronto, Canada
University of Arkansas for Medical Sciences IRB
🇺🇸
Little Rock, Arkansas, United States
Oulu University Hospital
🇫🇮
Oulu, Finland
CHU Amiens-Picardie
🇫🇷
Amiens Cedex 1, France
Northwestern Memorial Hospital
🇺🇸
Chicago, Illinois, United States
Beth Israel Deaconess Medical Center
🇺🇸
Boston, Massachusetts, United States
Azienda Ospedaliero-Universitaria Careggi
🇮🇹
Firenze, Italy
Universitatsklinikum Carl Gustav Carus
🇩🇪
Dresden, Germany
Fakultni nemocnice Ostrava, Klinika hemato-onkologicka
🇨🇿
Ostrava, Czechia
Hopital Saint Eloi
🇫🇷
Montpellier, France
Eastern Regional Health Authority
🇨🇦
St. John's, Canada
CHU de Nice-l Archet
🇫🇷
Nice, France
Petz Aladar Egyetemi Oktato Korhaz II. Belgyogyaszat - Hematologial Osztaly
🇭🇺
Gyor, Hungary
CHU de Poitiers - Hopital de la Miletrie
🇫🇷
Poitiers, France
Tom Baker Cancer Centre
🇨🇦
Calgary, Canada
Hopital Saint Louis
🇫🇷
Paris, France
CHU de Rennes- Hopital Pontchaillou
🇫🇷
Rennes Cedex 9, France
Hopital Henri Mondor
🇫🇷
Creteil, France
Institut Paoli Calmettes
🇫🇷
Marseille, France
Institut Gustave Roussy
🇫🇷
Paris, France
Helsinki University Central Hospital
🇫🇮
Helsinki, Finland
CHU de Grenoble Alpes
🇫🇷
La Tronche, France
Centre Hospitalier Lyon Sud
🇫🇷
Pierre Benite, France
Oslo University Hospital
🇳🇴
Oslo, Norway
Christchurch Hospital
🇳🇿
Christchurch, New Zealand
Istituto Oncologico Della Svizzera Italiana- IOSI, EOC, Clinica di Ematologia
🇨🇭
Bellinzona, Switzerland
University of Miami Hospital and Clinics / Sylvester Comprehensive Cancer Center
🇺🇸
Miami, Florida, United States
DUHS Duke Cancer Center
🇺🇸
Durham, North Carolina, United States
The University of Texas MD Anderson Cancer Center
🇺🇸
Houston, Texas, United States
Sir Charles Gairdner Hospital
🇦🇺
Nedlands, Western Australia, Australia
University of Oklahoma Health Sciences Center
🇺🇸
Oklahoma City, Oklahoma, United States
Tennessee Oncology, PLLC
🇺🇸
Nashville, Tennessee, United States
Huntsman Cancer Institute/University of Utah
🇺🇸
Salt Lake City, Utah, United States
University of Alabama Birmingham
🇺🇸
Birmingham, Alabama, United States
Oregon Health & Science University Pharmacy Services
🇺🇸
Portland, Oregon, United States
U.O di Ematologia, Ospedale San Gerardo- ASST Monza
🇮🇹
Monza, Italy
University Hospitals Birmingham NHS Foundation Trust
🇬🇧
Birmingham, United Kingdom
Kent and Canterbury Hospital- East Kent Hospitals University NHS Foundation Trust
🇬🇧
Canterbury, United Kingdom
Oxford University Hospitals NHS Foundation Trust
🇬🇧
Oxford, United Kingdom
Robert-Bosch-Krankenhaus, GmBH, Hamatologie, Onkologie und Palliativmedizin
🇩🇪
Stuttgart, Germany
City of Hope
🇺🇸
Duarte, California, United States
UC San Diego Moores Cancer Center
🇺🇸
La Jolla, California, United States
Stanford Cancer Institute
🇺🇸
Palo Alto, California, United States
University of Kansas Clinical Research Center
🇺🇸
Fairway, Kansas, United States
Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center
🇺🇸
Baltimore, Maryland, United States
Massachusetts General Hospital
🇺🇸
Boston, Massachusetts, United States
University of Minnesota Medical Center, Fairview
🇺🇸
Minneapolis, Minnesota, United States
Roswell Park Cancer Institute
🇺🇸
Buffalo, New York, United States
Weill Cornell Medicine-New York Presbyterian Hospital
🇺🇸
New York, New York, United States
Washington University School of Medicine - Siteman Cancer Center
🇺🇸
Saint Louis, Missouri, United States
Memorial Sloan Kettering Cancer Center
🇺🇸
New York, New York, United States
Mount Sinai Health System
🇺🇸
New York, New York, United States
Columbia University Medical Center - Herbert Irving Pavilion
🇺🇸
New York, New York, United States
Hospital of the University of Pennsylvania
🇺🇸
Philadelphia, Pennsylvania, United States
Prisma Health Cancer Center
🇺🇸
Greenville, South Carolina, United States
Texas Oncology - Baylor Charles A. Simmons Cancer Center
🇺🇸
Dallas, Texas, United States
UT Southwestern Medical Center
🇺🇸
Dallas, Texas, United States
Seattle Cancer Care Alliance
🇺🇸
Seattle, Washington, United States
Gosford Hospital
🇦🇺
Gosford, New South Wales, Australia
Icon Cancer Foundation
🇦🇺
South Brisbane, Queensland, Australia
Royal North Shore Hospital
🇦🇺
St Leonards, New South Wales, Australia
Prince of Wales Hospital
🇦🇺
Randwick, New South Wales, Australia
Westmead Hospital
🇦🇺
Westmead, New South Wales, Australia
Flinders Medical Center
🇦🇺
Bedford Park, South Australia, Australia
Royal Adelaide Hospital
🇦🇺
Adelaide, South Australia, Australia
Royal Hobart Hospital
🇦🇺
Hobart, Tasmania, Australia
Eastern Health
🇦🇺
Box Hill, Victoria, Australia
Monash Medical Centre
🇦🇺
Clayton, Victoria, Australia
Queen Mary Hospital
🇭🇰
Hong Kong, Hong Kong
Cabrini Hospital Malvern
🇦🇺
Malvern, Victoria, Australia
Peninsula Private Hospital
🇦🇺
Frankston, Victoria, Australia
Barwon Health, University Hospital Geelong
🇦🇺
Geelong, Victoria, Australia
The Alfred Hospital
🇦🇺
Melbourne, Victoria, Australia
Royal Melbourne Hospital
🇦🇺
Parkville, Victoria, Australia
Uniklinikum Salzburg
🇦🇹
Salzburg, Austria
ZNA Middelheim
🇧🇪
Antwerpen, Belgium
Hanusch kranhenkaus, 3. Medizinische Abteilung
🇦🇹
Vienna, Austria
ULB Hopital Erasme
🇧🇪
Brussels, Belgium
AZ Turnhout, Campus St. Elisabeth
🇧🇪
Turnhout, Belgium
Cliniques Universitaires Saint-Luc
🇧🇪
Brussels, Belgium
UZ Brussel
🇧🇪
Brussels, Belgium
UZ Leuven
🇧🇪
Leuven, Belgium
Hopital Haut-Leveque
🇫🇷
Pessac Cedex, France
Fakultni nemocnice Olomouc, Hemato-onkologicka klinika
🇨🇿
Olomouc, Czechia
QEII Health Sciences Centre
🇨🇦
Halifax, Canada
CHU de Nantes
🇫🇷
Nantes, France
Universitatsmedizin der Johannes Gutenberg Universitat Mainz, III. Medizinische Klinik und Poliklinik
🇩🇪
Braunschweig, Germany
Marien hospital, klinik fur onkologie, hamatologie und palliavmedizin
🇩🇪
Duesseldorf, Germany
Universitatsklinikum Essen
🇩🇪
Essen, Germany
Universitat Leipzig
🇩🇪
Leipzig, Germany
Princess Margaret Hospital
🇭🇰
Hong Kong, Hong Kong
Tuen Mun Hospital
🇭🇰
Hong Kong, Hong Kong
Kaposi Mor Teaching Hospital
🇭🇺
Kaposvar, Hungary
Debreceni Egyetem Klinikai Központ
🇭🇺
Debrecen, Hungary
Semmelweis Egyetem Belgyógyászati és Hematológiai Kilnika
🇭🇺
Budapest, Hungary
The Chinese University of Hong Kong, Prince of Wales Hospital
🇭🇰
Hong Kong, Hong Kong
Hospital Clinico Universitario de Valencia
🇪🇸
Valencia, Spain
Bács-Kiskun Megyei Kórház
🇭🇺
Kecskemet, Hungary
University of Pecs
🇭🇺
Pecs, Hungary
U.O Ematologica- ASST degli Spedali Civili di Brescia
🇮🇹
Brescia, Italy
SzSzB Megyei Korhazak es Egyetemi Oktatokorhaz
🇭🇺
Nyiregyhaza, Hungary
Szent Borbála Hospital
🇭🇺
Tatabanya, Hungary
SC Ematologica- Azienda Ospedaliera Nazionale SS. Antonio e Biagio e C. Arrigo
🇮🇹
Alessandria, Italy
U.O.C Ematologia - Dipartimento di Medicina Interna, Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico
🇮🇹
Milan, Italy
S. C. Ematologia Azienda Ospedaliero - Universitaria Maggiore Della Carita
🇮🇹
Novara, Italy
Azienda Ospedaliera Ospedali Riuniti Marche Nord
🇮🇹
Pesaro, Italy
University Medical Center Groningen
🇳🇱
Groningen, Netherlands
SC di Oncoematologia - Azienda Ospedaliera Santa Maria
🇮🇹
Terni, Italy
SC Ematologica, ASST Sette Laghi, Ospedale di Circolo e Fondazione Macchi
🇮🇹
Varese, Italy
Auckland City Hospital
🇳🇿
Grafton, New Zealand
Waikato Hospital
🇳🇿
Hamilton, New Zealand
Medisch Centrum Leeuwarden
🇳🇱
Leeuwarden, Netherlands
Southern District Health Board
🇳🇿
Dunedin, New Zealand
Midcentral District Health Board
🇳🇿
Palmerston North, New Zealand
Haukeland Universitetssjukehus, seksjon for blodsjukdommar- klinisk studieteam
🇳🇴
Bergen, Norway
Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie, Oddzial Kliniczny Hematologii
🇵🇱
Krakow, Poland
Stavanger universitetssjukehus
🇳🇴
Stavanger, Norway
Centrum Onkologii Ziemi Lubelskiej im. św. Jana z Dukli
🇵🇱
Lublin, Poland
Hospital da Luz
🇵🇹
Lisbon, Portugal
Centro Hospitalar Universitario Sao Joao. E.P.E
🇵🇹
Porto, Portugal
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu
🇵🇱
Wroclaw, Poland
Centro Clinico Academico de Braga, Hospital de Braga, E.P.E
🇵🇹
Braga, Portugal
Centro Hospitalar Vila Nova de Gaia/Espinho
🇵🇹
Porto, Portugal
Hospital del Mar
🇪🇸
Barcelona, Spain
Hospital Universitari Vall D'Hebron
🇪🇸
Barcelona, Spain
Area Sanitaria de Santiago de Compostela y Barbanza. Complejo Hospitalario Universitario de SantiagoD
🇪🇸
A Coruña, Spain
OSI Araba, Hospital Universitario de Alava, Hospital Txagorritxu
🇪🇸
Alava, Spain
Institut Catala d'Oncologia Girona
🇪🇸
Girona, Spain
MD Anderson Cancer Center Madrid
🇪🇸
Madrid, Spain
Institut Catala d'Oncologia, Hospital Duran i Reynals
🇪🇸
L´Hospitalet de Llobregat, Spain
Hospital Universitario Fundacion Jimenez Diaz
🇪🇸
Madrid, Spain
Hospital Universitario La Paz, Edificio General, 6 Planta. Despacho de Hematologia
🇪🇸
Madrid, Spain
Hospital Universitario Quironsalud Madrid. Servico de Hematologica y Hemoterapia
🇪🇸
Madrid, Spain
Hospital Regional Universitario de Malaga
🇪🇸
Malaga, Spain
Centro Hospitalar Universitario Sao Joao
🇪🇸
Pamplona, Spain
Complejo Asistencial Universitario de Salamanca- Hospital Clinico Universitario de Salamanca
🇪🇸
Salamanca, Spain
Hospital Universitario Virgen del Rocio
🇪🇸
Sevilla, Spain
Universitaetsspital Zurich - Klinik fur Medizinische Onkologie und Hematologie
🇨🇭
Zurich, Switzerland
University of Bern
🇨🇭
Bern, Switzerland
Gazi Universitesi Tip Fakultesi
🇹🇷
Ankara, Turkey
Hematoloji Bilim Dali, Yenimahalle
🇹🇷
Ankara, Turkey
Mersin University Medical
🇹🇷
Mersin, Turkey
Dokuz Eylul Universitesi Tip Fakultesi Onkoloji Enstitusu
🇹🇷
Inciralt, Turkey
Ankara Universitesi Tip Fakultesi Cebeci Hastanesi
🇹🇷
Ankara, Turkey
Tekirdag Namik Kemal Universitesi Tip Fakultesi
🇹🇷
Tekirdag, Turkey
United Lincolnshire Hospital NHS Trust
🇬🇧
Boston, United Kingdom
Champalimaud Foundation
🇵🇹
Lisbon, Portugal
Baylor College of Medicine
🇺🇸
Houston, Texas, United States
Akershus University Hospital
🇳🇴
Loerenskog, Norway
Instituto Portugues de Oncologia do Porto Francisco Gentil, EPE
🇵🇹
Porto, Portugal
Fox Chase Cancer Center
🇺🇸
Philadelphia, Pennsylvania, United States
Chu Ucl Namur Site Godinne
🇧🇪
Yvoir-Godinne, Belgium
University of California, Davis Comprehensive Cancer Center
🇺🇸
Sacramento, California, United States
Moffitt Cancer Center
🇺🇸
Tampa, Florida, United States
Tulane Medical Center
🇺🇸
New Orleans, Louisiana, United States
University of Michigan Medical School
🇺🇸
Ann Arbor, Michigan, United States
Mid America Division, Inc.
🇺🇸
Kansas City, Missouri, United States
University of North Carolina at Chapel Hill
🇺🇸
Chapel Hill, North Carolina, United States
Froedtert Hospital & the Medical College of Wisconsin
🇺🇸
Milwaukee, Wisconsin, United States
Hong Kong Sanatorium & Hospital
🇭🇰
Hong Kong, Hong Kong